In:
Frontiers in Cellular and Infection Microbiology, Frontiers Media SA, Vol. 12 ( 2022-6-29)
Abstract:
To investigate the effect of Bifidobacterium animalis B94 on the prevention and treatment of liver injury in rats and to elucidate the underlying mechanism of this relationship. Methods Specific pathogen-free (SPF) rats were selected as the healthy control group, liver injury group and B94 treatment group, with 6 rats in each group. After the model was established, the experimental animals were tested for serum liver function indicators, gut microbiota composition, metabolite composition, and histopathology. Results The albumin/globulin ratio and serum TBA, alanine aminotransferase, aspartate aminotransferase, and indirect bilirubin levels in the B94 treatment group were significantly lower than those in the liver injury group. 16S rRNA analysis showed that the gut microbiota of the three groups of rats were significantly different. Metabolic profile analysis showed that there were significant differences in the gut metabolomes of the three groups. Haematoxylin–eosin staining of the intestinal mucosa and liver tissues showed that the degree of liver and intestinal tissue damage in the B94 treatment group was significantly lower than that in the liver injury group. Conclusion Bifidobacterium animalis B94 can affect the process of liver injury in rats by improving liver function, reducing intestinal damage, and regulating gut microbiota and metabolite production.
Type of Medium:
Online Resource
ISSN:
2235-2988
DOI:
10.3389/fcimb.2022.914684
DOI:
10.3389/fcimb.2022.914684.s001
DOI:
10.3389/fcimb.2022.914684.s002
DOI:
10.3389/fcimb.2022.914684.s003
DOI:
10.3389/fcimb.2022.914684.s004
DOI:
10.3389/fcimb.2022.914684.s005
DOI:
10.3389/fcimb.2022.914684.s006
DOI:
10.3389/fcimb.2022.914684.s007
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2619676-1
Permalink